Addressing Type 2 Inflammation in Atopic Dermatitis: Individualizing Care Across Populations

Addressing Type 2 Inflammation in Atopic Dermatitis: Individualizing Care Across Populations is organized by National Association for Continuing Education (NACE).

Start Date: May 01, 2019
Expiration Date: Jul 01, 2020

Target Audience: Primary Care Providers

Credit(s): 
• 1.0 AMA PRA Category 1 Credit™
• 1.0 AANP Contact hour which includes 0.75 pharmacology hours

Estimated Time To Complete CME Activity: 1.0 Hour

Summary:
Atopic dermatitis (AD) is a multifactorial, chronic inflammatory and heterogeneous disorder that affects up to 20% of children and up to 3% of adults. The disease is characterized by intense itching, secondary skin infections, and recurrent eczematous lesions, and poses a significant burden on healthcare resources and patients' quality of life.

There is a wide variation in knowledge, competence and practice patterns among clinicians regarding the assessment and management of atopic dermatitis and its comorbidities. To ideally address the variation in individual knowledge, competence and practice patterns, the proposed curriculum is designed to provide learners with a serial learning curriculum with personalized learner pathways. This initial self-assessment activity will discuss the pathogenesis of AD, particularly the role of the Th2 pathway to increase ability to recognize the clinical presentations and differential diagnosis of AD. It will provide information on the current research and trial data supporting treatment for individualized treatment of AD with consideration to the full spectrum of treatment options and disease severity, recognize the risks and safety profiles for effective AD management, and integrating the recognition of comorbidities into management.

After completing this activity, learners will be invited to participate in a subset of subsequent brief, single-issue focused “micro-activities” that best address their learning gaps, covering topics that they have not yet mastered, as demonstrated in this self-assessment activity.

Learning Objectives:
At the conclusion of this activity, the learner will be able to:
• Describe the pathogenesis of AD, particularly the role of the Th2 pathway.
• Demonstrate increased ability to recognize the clinical presentations and differential diagnosis of AD.
• Discuss the current research and trial data supporting treatment options for AD.
• Individualize AD treatment with consideration to the full spectrum of treatment options and disease severity.
• Recognize the risks and safety profiles of current treatments for effective AD management.
• Integrate the recognition of comorbidities into the management AD

Additional details will be posted as soon as information is available.